An FDA advisory panel has voted to allow compounding pharmacies to produce copies of certain popular peptide-based weight loss and diabetes drugs, specifically tirzepatide, semaglutide, and retatrutide, during periods of drug shortage. The panel rejected a proposal to allow compounding for a fourth peptide. This decision is a significant victory for the compounding industry and patients seeking lower-cost alternatives, but it raises safety concerns among FDA staff regarding the quality of non-FDA approved versions.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.